Kranjc A, Kikelj D
Faculty of Pharmacy, University of Ljubljana, Slovenia.
Curr Med Chem. 2004 Oct;11(19):2535-47. doi: 10.2174/0929867043364432.
The search for an ideal anticoagulant has spanned decades and has resulted in several approaches and the identification of novel target molecules for preventing and treating thrombosis. The first group of new anticoagulant agents acting through direct inhibition of coagulation factors were inhibitors of thrombin, but factor Xa inhibitors and, most recently, factor VIIa inhibitors have become attractive candidates. The structures of thrombin, factor Xa and factor VIIa show similarities in their active sites and, for this reason, attempts have been made to develop synthetic agents containing in a single molecule inhibitory activity against two of the enzymes of the blood coagulation cascade. Such dual inhibitors are now in preclinical studies and are, potentially, new anticoagulant drugs with improved properties. The emphasis of this review will be placed on dual inhibitors of thrombin/factor Xa and factor Xa/factor VIIa. Comparison of the active sites of these enzymes is included for better understanding of the structural demands to be met in designing effective dual inhibitors.
寻找理想的抗凝剂已经历经数十年,产生了多种方法,并确定了预防和治疗血栓形成的新型靶分子。第一类通过直接抑制凝血因子起作用的新型抗凝剂是凝血酶抑制剂,但因子Xa抑制剂以及最近的因子VIIa抑制剂已成为有吸引力的候选药物。凝血酶、因子Xa和因子VIIa的结构在其活性位点上显示出相似性,因此,人们试图开发在单个分子中含有针对凝血级联反应中两种酶的抑制活性的合成药物。此类双重抑制剂目前正处于临床前研究阶段,有可能成为具有更好特性的新型抗凝药物。本综述将重点关注凝血酶/因子Xa双重抑制剂和因子Xa/因子VIIa双重抑制剂。为了更好地理解设计有效双重抑制剂时需要满足的结构要求,本文还对这些酶的活性位点进行了比较。